Observational study · people

LL-37 blood levels highest in adults with lung tuberculosis

Checked against the paper Observational studyPublished by PepVault

The takeaway

Natural LL-37 levels in the blood run higher during lung infections, most of all in TB; this is a measurement study, not a test of LL-37 as a treatment.

Kind
Observational study
Studied in
People
Published
2017
Journal
Clin Invest Med

What they tested

The team wanted to know how blood levels of the body's own LL-37 differ between adults with lung tuberculosis, adults with bacterial pneumonia, and healthy people.

How the study was done

An observational comparison of 30 adults with lung tuberculosis (TB), 30 with pneumonia from Gram-positive bacteria, 30 with pneumonia from Gram-negative bacteria, and 30 healthy controls. LL-37 in serum (the liquid part of blood) was measured with ELISA, a lab test that detects a specific protein.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

People with TB had an average serum LL-37 of 13.94±5.13 ng/mL (mean ± SEM, a measure of how precise the average is). That was significantly higher than in Gram-positive pneumonia (7.87±4.58 ng/mL, P=0.00077), in Gram-negative pneumonia (10.27±3.60 ng/mL, P=0.00730), and in healthy controls (1.75±0.71 ng/mL, P=0.00004). The authors read this as a sign that LL-37 is an important part of the body's defense in bacterial lung infections, especially when the germ lives inside cells.

What it doesn’t show

This was a measurement study of the body's own LL-37 in blood, with no treatment arm, so it tells us nothing about the effects of taking the peptide. The groups were small at 30 each, and a link between higher levels and infection is not proof that LL-37 caused any benefit.

The paper

Majewski et al. Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases. Clin Invest Med. 2017.

The compound

More studies on LL-37

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo